美媒：特朗普称美政府正“考虑”对大麻重新分类，将其列为“危害性较低毒品”

Core Viewpoint - The U.S. government is considering reclassifying marijuana as a "lower-risk drug," which could significantly benefit the multi-billion dollar cannabis industry by easing research restrictions [1][3]. Group 1: Government Actions and Implications - President Trump indicated that the government is contemplating the reclassification of marijuana to facilitate research, which has been hindered under its current classification as a Schedule I drug [3]. - The reclassification would not legalize marijuana or decriminalize its use but would lower research barriers and enhance the legal operating environment for businesses in the cannabis sector [4]. - The potential shift in regulation aligns with a broader trend of states legalizing medical and recreational marijuana, reflecting changing societal attitudes towards cannabis [5]. Group 2: Industry Impact and Lobbying - The cannabis industry has seen significant lobbying efforts, with over $22.4 million spent on political lobbying related to cannabis products from 2018 to 2022 [5]. - The push for legalization and reclassification is closely tied to financial interests and political lobbying, indicating a strong influence of interest groups in shaping cannabis policy [5]. - Despite the potential benefits of reclassification, concerns remain regarding the health impacts of marijuana use, including addiction and mental health issues [4].